About Transcription factor E2F7
Transcription factor E2F7 (E2F7) is a protein
from Homo sapiens identified by UniProt accession
Q96AV8, 911 residues long.
MolForge cross-references it against 0 known binders and
134 disease associations.
Target properties
| Protein name | Transcription factor E2F7 |
| UniProt accession | Q96AV8 |
| Gene | E2F7 |
| Organism | Homo sapiens |
| Length | 911 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-Q96AV8-F1 | alphafold | PREDICTED | 50.67 | — |
Amino-acid sequence (911 residues)
MEVNCLTLKD LISPRQPRLD FAVEDGENAQ KENIFVDRSR MAPKTPIKNE PIDLSKQKKF TPERNPITPV KFVDRQQAEP WTPTANLKML ISAASPDIRD REKKKGLFRP IENKDDAFTD SLQLDVVGDS AVDEFEKQRP SRKQKSLGLL CQKFLARYPS YPLSTEKTTI SLDEVAVSLG VERRRIYDIV NVLESLHLVS RVAKNQYGWH GRHSLPKTLR NLQRLGEEQK YEEQMAYLQQ KELDLIDYKF GERKKDGDPD SQEQQLLDFS EPDCPSSSAN SRKDKSLRIM SQKFVMLFLV SKTKIVTLDV AAKILIEESQ DAPDHSKFKT KVRRLYDIAN VLTSLALIKK VHVTEERGRK PAFKWIGPVD FSSSDEELVD VSASVLPELK RETYGQIQVC AKQKLARHGS FNTVQASERI QRKVNSEPSS PYREEQGSGG YSLEIGSLAA VYRQKIEDNS QGKAFASKRV VPPSSSLDPV APFPVLSVDP EYCVNPLAHP VFSVAQTDLQ AFSMQNGLNG QVDVSLASAA SAVESLKPAL LAGQPLVYVP SASLFMLYGS LQEGPASGSG SERDDRSSEA PATVELSSAP SAQKRLCEER KPQEEDEPAT KRQSREYEDG PLSLVMPKKP SDSTDLASPK TMGNRASIPL KDIHVNGQLP AAEEISGKAT ANSLVSSEWG NPSRNTDVEK PSKENESTKE PSLLQYLCVQ SPAGLNGFNV LLSGSQTPPT VGPSSGQLPS FSVPCMVLPS PPLGPFPVLY SPAMPGPVSS TLGALPNTGP VNFSLPGLGS IAQLLVGPTA VVNPKSSTLP SADPQLQSQP SLNLSPVMSR SHSVVQQPES PVYVGHPVSV VKLHQSPVPV TPKSIQRTHR ETFFKTPGSL GDPVLKRRER NQSRNTSSAQ RRLEIPSGGA D
Explore Transcription factor E2F7 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets